Pharmaceutical giant Johnson & Johnson is investing in direct-to-consumer telehealth company Thirty Madison. New York City-based Thirty Madison offers telehealth visits and online prescriptions for drugs for hair loss, migraines and acid reflux, according to a FierceHealthcare report.
Thirty Madison has scored $47 million in a series B funding round led by healthcare venture capital firm Polaris Partners. Johnson & Johnson’s innovation arm, Johnson & Johnson Innovation – JJDC, Inc., joined the round as a new investor. Existing investors Maveron and Northzone also participated in that round.